🔶 Definium Therapeutics Earnings Call Q2 August 06, 2026 🔶

Definium Therapeutics reports positive phase 3 study results for DT-120 ODT, a candidate for generalized anxiety disorder, and announces upcoming data for the same substance in major depressive disorder. These results form a critical milestone in establishing the potential for rapid and durable clinical benefits from this treatment. The clinical program aims to address the significant unmet needs for patients living with anxiety and depression by introducing a potentially groundbreaking, first-in-class psychiatric intervention. Clinical progression and commercial readiness remain the key corporate priorities for the year.